Janssen is collaborating with Verana Health, a leader in transforming clinical data into actionable Real-World Evidence in ophthalmology and urology. This partnership leverages Real-World Data (RWD) from the American Academy of Ophthalmology Intelligent Research in SIGHT Registry (IRIS® Registry), to characterize baseline patient attributes, disease progression and treatment-based outcomes for patients being treated for diabetic macular edema. In this partnership, Janssen is also focusing on early-stage prostate cancer with the launch of a pilot program to curate and evaluate de-identified data from the American Urological Association Quality Registry.
Janssen partners with Tempus, a leader in Artificial Intelligence (AI) and precision medicine, to develop a predictive Machine Learning (ML) model to improve enrollment in biomarker-driven clinical trials in the oncology portfolio. The collaboration is part of a multi-year agreement, leveraging the capabilities of Tempus with those of Janssen with the intent of bringing the power of precision medicine to address the needs of cancer patients. Janssen and Tempus will use large multimodal datasets in oncology to build and deploy AI-enabled diagnostics to rapidly accelerate the drug development process, increasing probability of success and reducing the overall cost. Janssen has also joined The TIME Trial Network, Tempus’s program which brings clinical trials to communities across the country, offering patients access to novel therapies under development. As part of the program, Tempus screens thousands of patients weekly against each trial’s criteria, matching patients and rapidly activating sites to enroll patients in clinical studies based on their eligibility in as few as 10 days.
In Janssen’s ongoing work to build better medicines for patients, Janssen has entered into two separate partnerships with Datavant to link RWD and clinical data sources. Under the first agreement, Janssen is integrating disparate data sets to create rich, longitudinal real-world and clinical datasets to better understand both therapeutics and the holistic patient journey. In the second agreement, established as part of Janssen’s Series B investment in Datavant in 2020, Janssen will offer guidance and insights to Datavant’s strategy in relation to new product and service offerings, including efforts to link clinical trial data to real-world evidence to enhance clinical trial execution.
In 2020, Johnson & Johnson completed a Series B1 investment in Aetion, a women-led healthcare technology company specializing in the analysis of RWD to enable the next generation of decision ready evidence for regulatory, policy and pricing decisions. The Aetion Evidence Platform® is scientifically validated software for performing regulatory-grade analytics at scale and was selected by the FDA to help establish novel approaches to drug approval and safety processes, including to inform the Agency’s response to the COVID-19 pandemic. Janssen Data Science uses Aetion's technology and services to inform critical decisions and help guide product development. This partnership provides an opportunity for mutual influence between Janssen Data Science and JJDC with Aetion, on topics including strategy, shared insights, teams and advisors.
In early 2021, Johnson & Johnson co-led a Series C investment in Paige AI, a global leader in digital diagnostics focused on providing AI tools that will enable faster and more accurate diagnosis and patient treatment decisions to be made. This partnership expands on Janssen and Paige’s development of AI-based capabilities both within and outside of oncology and the delivery of these capabilities to laboratories and clinicians globally. Prior to this partnership, Janssen Oncology and Data Science teams partnered with Paige AI to automate the difficult and time-consuming task of assessing tissue samples from residual prostate tumors following neoadjuvant treatment.
Janssen R&D entered into a multi-disease collaboration with ConcertAI, a market leader for RWD and enterprise AI technology solutions for precision oncology. The collaboration provides Janssen access to ConcertAI use-case engineered RWD products and enabled their use across key disease areas of the Janssen Oncology portfolio. Together, these data sets provide an integrated and holistic view of the patient journey with greater clinical depth to support translational sciences, clinical study design and RWD applications for regulatory submissions. Janssen is also the first to use ConcertAI’s Genome360, a translational-grade real world solution that integrates in-depth clinical and next generation sequencing characterization of a patient’s cancer. Also, Janssen is leveraging ConcertAI’s ERACE capability, a registry and initiative focused on improving health equality and diversity within oncology clinical research.
UK Biobank is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants. UK Biobank’s database, which includes blood samples, heart and brain scans and genetic data of the 500,000 volunteer participants, is globally accessible to approved researchers who are undertaking health-related research that’s in the public interest. Janssen, together with the UK government, the Wellcome Trust, and a consortium of pharmaceutical partners, is enhancing the genetic data in this database through the UK Biobank Whole Genome Sequencing project. This project reads and assembles the genomic sequence of all 500,000 UK Biobank volunteers and enables the global scientific community to analyze, understand, diagnose, treat and work to prevent life-threatening diseases such as cancer, heart disease, depression, forms of dementia and much more. Whole genome sequencing began in September 2019 with the full data set accessible by early 2022. Janssen has also recently partnered with a broader consortium of pharmaceutical partners to generate proteomics data consisting of ~1,500 proteins on 53,000 UK Biobank participants. The complete dataset will become available near the end of 2021.
In 2019, Janssen R&D partnered with a leading biomedical, AI startup, nference, to leverage their Data Science-powered research portal known as the nferX platform, that connects biological information to disease conditions and therapeutic mechanisms. Using this portal, Janssen R&D collaborated with nference physicians and data scientists to deeply profile the coronavirus receptor (ACE2) for 25 different tissues, revealing a comprehensive map of possible SARS-COV-2 infectivity across cell types and organ systems. The nferX single cell application, a first-in-class software resource that synthesizes disparate single cell RNA-sequencing (scRNA-seq) data sets in order to help scientists rapidly generate and pressure-test new hypotheses, has been made available to all scientists in the academic community.